3rd World ADC Asia 2024 Grand Hyatt Incheon, Jung-gu
The year 2024 has been considered the ‘coming of age’ era for antibody-drug conjugates, in great part due to the remarkable resurgence in drug development across the Asia-Pacific region. This part of the world is taking the ADC industry by storm with high-profile deals, multiple approvals, multiple ADCs moving into clinical trials, and novel targets being explored just to name some advancements.
Back by popular demand after a short break, the 3rd World ADC Asia is bringing together pioneers and key opinion leaders across mega-pharma and biotechnology focusing on China, Japan, Taiwan, South Korea and Singapore. They’ll be sharing their most pressing challenges, novel payloads, conjugation, and linker innovations to inform ADC development and improve targeting accuracy.
Alongside exclusive insights on the latest clinical developments taking place in the space, the many networking opportunities available will also help you build the strategic collaborations required to meet regulatory standards, understand CMC manufacturing, deal with supply chain issues, and more.